| Literature DB >> 18291615 |
Nabil Ben Chaabane1, Hichem Loghmari, Wissem Melki, Olfa Hellara, Leila Safer, Fethia Bdioui, Hammouda Saffar.
Abstract
Chronic viral hepatitis remains a major problem among patients with chronic renal failure. Hepatitis B and C viruses are frequent among dialysis patients and after renal transplantation and may significantly diminish the survival of both the patient and the graft. Hepatitis B and C viral infection in these patients is often characterized by normal transaminase levels despite viremia and progressive liver lesions. Liver biopsy remains essential for assessing the extent of liver disease. Cirrhosis is a contraindication to transplantation of only a kidney, because of elevated morbidity and mortality. A combined as liver-kidney transplantation may be considered. The best treatment of hepatitis infections is preventive: vaccination against the hepatitis B virus and attentive hygiene, especially to prevent nosocomial transmission. Among patients not awaiting transplant, antiviral treatment should be reserved for patients with active or even fibrotic liver disease. For hemodialysis patients awaiting kidney transplant: Alpha interferon is ineffective and poorly tolerated by dialysis patients. Lamivudine is effective and well tolerated, but its long-term efficacy and its optimal effective dose in dialysis patients remain unknown.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18291615 DOI: 10.1016/j.lpm.2007.10.013
Source DB: PubMed Journal: Presse Med ISSN: 0755-4982 Impact factor: 1.228